Circuit-Bio develops a synthetic gene circuit platform that produces a combination of immune-stimulating proteins specifically in targeted tumor cells, addressing the challenges of poor efficacy and off-target activity in cancer immunotherapy. This technology transforms cancer cells into agents that elicit a robust anti-tumoral immune response, tailored to individual patient needs.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies often suffer from limited efficacy and off-target effects, failing to generate a robust and targeted immune response against tumors. Traditional approaches struggle to selectively activate the immune system within the tumor microenvironment, leading to systemic toxicity and reduced therapeutic benefit.
Solution
Circuit-Bio is developing a synthetic gene circuit platform that addresses these limitations by engineering tumor cells to locally produce a combination of immune-stimulating proteins (immunomodulators). These gene circuits are designed with multiple tumor-specific synthetic sensors, ensuring that the immunomodulatory proteins are exclusively expressed within the targeted tumor cells. By transforming cancer cells into "Trojan horses" that express these immunostimulatory proteins, Circuit-Bio aims to trigger a robust and long-term anti-tumoral immune response, tailored to individual patient needs and controlled by multiple synthetic cancer-specific sensors. This approach seeks to enhance efficacy while minimizing off-target activity, offering a next-generation solution for cancer immunotherapy.
Target Audience
The primary target audience includes cancer patients with solid tumors, oncologists seeking more effective and targeted immunotherapies, and pharmaceutical companies developing next-generation cancer treatments.
Features
- Logic-gated gene circuits that express multiple immune-stimulating proteins exclusively in targeted tumor cells.
- Multiple tumor-specific synthetic sensors for enhanced selectivity and specificity.
- Tunable circuit components adaptable to individual patient profiles.
- Pipeline programs focused on colon and breast cancer indications.